| Schedule of Basic and Diluted Earning Per Share |
| | | | | | | | | | | | | | | | | | | | | The following presents the detailed calculation of EPS: | | | | Year Ended December 31, | | (IN MILLIONS) | | 2020 | | 2019 | | 2018 | | EPS Numerator––Basic | | | | | | | Income from continuing operations attributable to Pfizer Inc. | | $ | 6,985 | | | $ | 10,838 | | | $ | 3,825 | | | Less: Preferred stock dividends––net of tax | | — | | | 1 | | | 1 | | Income from continuing operations attributable to Pfizer Inc. common shareholders | | 6,984 | | | 10,837 | | | 3,824 | | | | | | | | | | | | | | | | | Income from discontinued operations––net of tax | | 2,631 | | | 5,435 | | | 7,328 | | Net income attributable to Pfizer Inc. common shareholders | | $ | 9,616 | | | $ | 16,272 | | | $ | 11,152 | | | EPS Numerator––Diluted | | | | | | | Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions | | $ | 6,985 | | | $ | 10,838 | | | $ | 3,825 | | | Income from discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions | | 2,631 | | | 5,435 | | | 7,328 | | Net income attributable to Pfizer Inc. common shareholders and assumed conversions | | $ | 9,616 | | | $ | 16,273 | | | $ | 11,153 | | | EPS Denominator | | | | | | | | Weighted-average number of common shares outstanding––Basic | | 5,555 | | | 5,569 | | | 5,872 | | | Common-share equivalents: stock options, stock issuable under employee compensation plans convertible preferred stock and accelerated share repurchase agreements | | 77 | | | 106 | | | 105 | | Weighted-average number of common shares outstanding––Diluted | | 5,632 | | | 5,675 | | | 5,977 | | Anti-dilutive common stock equivalents(a) | | 4 | | | 2 | | | 2 | |
(a)These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
|